FDA Accepts SNY and REGNs Dupixent Re-Submitted sBLA for Urticaria
| NBHIX Fund | USD 14.90 0.07 0.47% |
Slightly above 53% of Neuberger Berman's investor base is interested to short. The analysis of overall sentiment of trading Neuberger Berman Equity mutual fund suggests that many investors are impartial at this time. Neuberger Berman's investing sentiment can be driven by a variety of factors including economic data, Neuberger Berman's earnings reports, geopolitical events, and overall market trends.
Neuberger |
The FDA is set to give its decision on SNY and REGNs sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
Read at zacks.com
 |
Neuberger Berman Fundamental Analysis
We analyze Neuberger Berman's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuberger Berman using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuberger Berman based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Neuberger Berman is currently under evaluation in net asset among similar funds. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Neuberger Berman Equity Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neuberger Berman mutual fund to make a market-neutral strategy. Peer analysis of Neuberger Berman could also be used in its relative valuation, which is a method of valuing Neuberger Berman by comparing valuation metrics with similar companies.
Peers
Neuberger Berman Related Equities
| NRAAX | Neuberger Berman | 0.82 | ||||
| NRACX | Neuberger Berman | 0.82 | ||||
| NRARX | Neuberger Berman | 0.81 | ||||
| NPNAX | Neuberger Berman | 0.60 | ||||
| NPNCX | Neuberger Berman | 0.50 | ||||
| NPRTX | Neuberger Berman | 0.49 | ||||
| NHS | Neuberger Berman | 0.39 | ||||
| NRABX | Neuberger Berman | 0.33 |
Other Information on Investing in Neuberger Mutual Fund
Neuberger Berman financial ratios help investors to determine whether Neuberger Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Neuberger with respect to the benefits of owning Neuberger Berman security.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |